Cargando…

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer

BACKGROUND: Sometimes the diagnosis of recurrent cancer in patients with a previous malignancy can be challenging. This prospective cohort study assessed the clinical utility of (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography ((18)F-FDG PET-CT) in the diagnosis of clinicall...

Descripción completa

Detalles Bibliográficos
Autores principales: You, J J, Cline, K J, Gu, C-S, Pritchard, K I, Dayes, I S, Gulenchyn, K Y, Inculet, R I, Dhesy-Thind, S K, Freeman, M A, Chan, A M, Julian, J A, Levine, M N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647251/
https://www.ncbi.nlm.nih.gov/pubmed/25942398
http://dx.doi.org/10.1038/bjc.2015.151
_version_ 1782401059502686208
author You, J J
Cline, K J
Gu, C-S
Pritchard, K I
Dayes, I S
Gulenchyn, K Y
Inculet, R I
Dhesy-Thind, S K
Freeman, M A
Chan, A M
Julian, J A
Levine, M N
author_facet You, J J
Cline, K J
Gu, C-S
Pritchard, K I
Dayes, I S
Gulenchyn, K Y
Inculet, R I
Dhesy-Thind, S K
Freeman, M A
Chan, A M
Julian, J A
Levine, M N
author_sort You, J J
collection PubMed
description BACKGROUND: Sometimes the diagnosis of recurrent cancer in patients with a previous malignancy can be challenging. This prospective cohort study assessed the clinical utility of (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography ((18)F-FDG PET-CT) in the diagnosis of clinically suspected recurrence of cancer. METHODS: Patients were eligible if cancer recurrence (non-small-cell lung (NSCL), breast, head and neck, ovarian, oesophageal, Hodgkin's or non-Hodgkin's lymphoma) was suspected clinically, and if conventional imaging was non-diagnostic. Clinicians were asked to indicate their management plan before and after (18)F-FDG PET-CT scanning. The primary outcome was change in planned management after (18)F-FDG PET-CT. RESULTS: Between April 2009 and June 2011, 101 patients (age, median 65 years; 55% female) were enroled from four cancer centres in Ontario, Canada. Distribution by primary tumour type was: NSCL (55%), breast (19%), ovarian (10%), oesophageal (6%), lymphoma (6%), and head and neck (4%). Of the 99 subjects who underwent (18)F-FDG PET-CT, planned management changed after (18)F-FDG PET-CT in 52 subjects (53%, 95% confidence interval (CI), 42–63%); a major change in plan from no treatment to treatment was observed in 38 subjects (38%, 95% CI, 29–49%), and was typically associated with (18)F-FDG PET-CT findings that were positive for recurrent cancer (37 subjects). After 3 months, the stated post-(18)F-FDG PET-CT management plan was actually completed in 88 subjects (89%, 95% CI, 81–94%). CONCLUSION: In patients with suspected cancer recurrence and conventional imaging that is non-diagnostic, (18)F-FDG PET-CT often provides new information that leads to important changes in patient management.
format Online
Article
Text
id pubmed-4647251
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46472512016-05-26 (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer You, J J Cline, K J Gu, C-S Pritchard, K I Dayes, I S Gulenchyn, K Y Inculet, R I Dhesy-Thind, S K Freeman, M A Chan, A M Julian, J A Levine, M N Br J Cancer Clinical Study BACKGROUND: Sometimes the diagnosis of recurrent cancer in patients with a previous malignancy can be challenging. This prospective cohort study assessed the clinical utility of (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography ((18)F-FDG PET-CT) in the diagnosis of clinically suspected recurrence of cancer. METHODS: Patients were eligible if cancer recurrence (non-small-cell lung (NSCL), breast, head and neck, ovarian, oesophageal, Hodgkin's or non-Hodgkin's lymphoma) was suspected clinically, and if conventional imaging was non-diagnostic. Clinicians were asked to indicate their management plan before and after (18)F-FDG PET-CT scanning. The primary outcome was change in planned management after (18)F-FDG PET-CT. RESULTS: Between April 2009 and June 2011, 101 patients (age, median 65 years; 55% female) were enroled from four cancer centres in Ontario, Canada. Distribution by primary tumour type was: NSCL (55%), breast (19%), ovarian (10%), oesophageal (6%), lymphoma (6%), and head and neck (4%). Of the 99 subjects who underwent (18)F-FDG PET-CT, planned management changed after (18)F-FDG PET-CT in 52 subjects (53%, 95% confidence interval (CI), 42–63%); a major change in plan from no treatment to treatment was observed in 38 subjects (38%, 95% CI, 29–49%), and was typically associated with (18)F-FDG PET-CT findings that were positive for recurrent cancer (37 subjects). After 3 months, the stated post-(18)F-FDG PET-CT management plan was actually completed in 88 subjects (89%, 95% CI, 81–94%). CONCLUSION: In patients with suspected cancer recurrence and conventional imaging that is non-diagnostic, (18)F-FDG PET-CT often provides new information that leads to important changes in patient management. Nature Publishing Group 2015-05-26 2015-05-05 /pmc/articles/PMC4647251/ /pubmed/25942398 http://dx.doi.org/10.1038/bjc.2015.151 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Clinical Study
You, J J
Cline, K J
Gu, C-S
Pritchard, K I
Dayes, I S
Gulenchyn, K Y
Inculet, R I
Dhesy-Thind, S K
Freeman, M A
Chan, A M
Julian, J A
Levine, M N
(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title_full (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title_fullStr (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title_full_unstemmed (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title_short (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
title_sort (18)f-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647251/
https://www.ncbi.nlm.nih.gov/pubmed/25942398
http://dx.doi.org/10.1038/bjc.2015.151
work_keys_str_mv AT youjj 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT clinekj 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT gucs 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT pritchardki 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT dayesis 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT gulenchynky 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT inculetri 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT dhesythindsk 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT freemanma 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT chanam 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT julianja 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer
AT levinemn 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographytodiagnoserecurrentcancer